Recent research has demonstrated that inhibiting YTHDF2 can suppress immune evasion and angiogenesis in HCC through the ETS variant transcription Factor 5 (ETV5)/PD-L1/VEGFA axis. The gene discussed is YTHDF2; the disease is hepatocellular carcinoma.